Perspective Therapeutics (CATX) Payables (2011 - 2026)

Perspective Therapeutics has disclosed Payables across 16 years of filings, most recently posting $26.5 million for Q1 2026.

• Payables for Q1 2026 came in at $26.5 million, up 202.05% year-over-year; the trailing twelve-month figure through Mar 2026 was $26.5 million (up 202.05% YoY), and the FY2025 annual result was $20.6 million, up 97.85% from the prior year.
• Payables came in at $26.5 million for Q1 2026 at Perspective Therapeutics, up from $20.6 million in the prior quarter.
• In the past five years, Payables ranged from a high of $26.5 million in Q1 2026 to a low of $150000.0 in Q2 2022.
• The 5-year median for Payables is $6.7 million (2023), against an average of $8.1 million.
• Across the five-year window, Payables slumped 73.83% in 2022 and surged 4352.0% in 2023, its largest moves.
• Perspective Therapeutics' Payables stood at $233000.0 in 2022, then surged by 2886.27% to $7.0 million in 2023, then soared by 49.4% to $10.4 million in 2024, then jumped by 97.85% to $20.6 million in 2025, then climbed by 29.05% to $26.5 million in 2026.
• The last three Payables figures came in at $26.5 million (Q1 2026), $20.6 million (Q4 2025), and $13.2 million (Q3 2025), per Business Quant data.